Does Previous Anti-thrombotic Use Affect the Course of Coronavirus Disease-2019?
Introduction: Proinflammatory cytokines, produced as an immune response in severe acute respiratory syndrome- coronavirus 2 infection, activate the coagulation cascade as well. In this study, we investigated the difference in the clinical course of patients who had been already using anti-thrombotic...
Saved in:
Published in | Istanbul medical journal Vol. 23; no. 4; pp. 301 - 305 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English Turkish |
Published |
Istanbul
Galenos Yayinevi Tic. Ltd
01.11.2022
Galenos Publishing House Galenos Yayinevi |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Introduction: Proinflammatory cytokines, produced as an immune response in severe acute respiratory syndrome- coronavirus 2 infection, activate the coagulation cascade as well. In this study, we investigated the difference in the clinical course of patients who had been already using anti-thrombotic therapy before coronavirus disease-2019 (COVID-19) for any reason compared to the group who had not. Methods: In this retrospective, multicenter study; patients who were hospitalized between March 11 and July 1, 2020 were divided into two main groups as who had been on anti-thrombotic therapy for any indication use previously at the time of admission or who had not been on anti-thrombotic therapy at the time of admission, and their selected clinical parameters were compared. Results: After analyzing the study population of 124 patients with a homogeneous distribution in terms of age and gender, the comparison of anti-thrombotic users and non-users showed no significant difference in hospitalization. There was a statistically significant decrease in mechanical ventilation apply rate, intensive care unit duration and mortality rate between the group using anti-thrombotic compared to the group not using it (p<0.05). Conclusion: It has already been shown that COVID-19 patients are more prone to thromboembolic events as it activates the coagulation cascade with the cytokine storm it creates and thus the mortality of COVID-19 infection increases significantly. Parallel to this fact the results of our study demonstrated that using anti-thrombotic therapy for any reason may affect the bad prognosis of the disease positively. Keywords: SARS-CoV-2, COVID-19, anti-trombotic treatments |
---|---|
ISSN: | 2619-9793 1304-8503 2148-094X |
DOI: | 10.4274/imj.galenos.2022.49035 |